Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.
You may also be interested in...
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.
Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings
The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.